Time Course and Role of Morphine Dose and Concentration in Intrathecal Granuloma Formation in Dogs: A Combined Magnetic Resonance Imaging and Histopathology Investigation

Background:Intrathecal morphine infusion leads to intrathecal granulomas. In dogs, the authors examined time course of granuloma formation and the role of concentration in granuloma development. Methods:Dogs were prepared with lumbar intrathecal catheters and vest-mounted pumps. To define the time course of granuloma formation, serial magnetic resonance imaging was performed in animals receiving 10 or 31 days of morphine infusion (12.5 mg/ml at 40 &mgr;l/h). At these times, morphine was removed from the infusate, and further magnetic resonance images were acquired over 14–35 additional days. To assess dose versus concentration, dogs received 28-day infusions of vehicle, 12 mg morphine/day as 12.5 mg/ml at 40 &mgr;l/h, or 1.5 mg/ml at 334 &mgr;l/h (12 mg/day) for 28 days. Additional dogs received 3 mg/day as 12.5 mg/ml at 10 &mgr;l/h. Results:Serial magnetic resonance images in dogs receiving morphine (12.5 mg/ml at 40 &mgr;l/h) revealed pericatheter-enhancing tissues as early as 3 days with a prominent signal by 10 days. Removal of morphine reduced the mass volume within 7 days. At a fixed infusion rate, the incidence of granuloma formation with the continuous intrathecal infusion of morphine ranged from 0 in vehicle-treated dogs to 100% in dogs treated with 12.5 mg/ml at 40 &mgr;l/h (12 mg/day). Infusion of 12 mg/day at 1.5 mg/ml (334 &mgr;l/h) resulted in granuloma in one of four animals. The authors found that infusion of morphine in different concentrations at a fixed rate resulted in a dose-dependent increase in concentration, with the granuloma-producing, dose-yielding lumbar cerebrospinal fluid morphine concentrations around 40 &mgr;g/ml. Conclusions:Serial magnetic resonance imaging showed a rapid formation and regression of the masses initiated by intrathecal morphine infusion. These masses are dependent on local concentration.

[1]  J. Bailes,et al.  A review of intrathecal morphine therapy related granulomas , 2006, European journal of pain.

[2]  R. Rosenquist,et al.  Intrathecal catheter tip inflammatory mass: a failure of clonidine to protect. , 2005, Anesthesiology.

[3]  J. Eisenach,et al.  Intrathecal, but not intravenous adenosine reduces allodynia in patients with neuropathic pain , 2003, Pain.

[4]  Brian R. Phillips,et al.  Epidural, Cerebrospinal Fluid, and Plasma Pharmacokinetics of Epidural Opioids (Part 1): Differences among Opioids , 2003, Anesthesiology.

[5]  C. Sommer,et al.  Chronically Infused Intrathecal Morphine in Dogs , 2003, Anesthesiology.

[6]  S. Hassenbusch,et al.  Safety of Chronic Intrathecal Morphine Infusion in a Sheep Model , 2003, Anesthesiology.

[7]  Marion R McMillan,et al.  Catheter-Associated Masses in Patients Receiving Intrathecal Analgesic Therapy , 2003, Anesthesia and analgesia.

[8]  R. Coffey,et al.  Inflammatory Mass Lesions Associated with Intrathecal Drug Infusion Catheters: Report and Observations on 41 Patients , 2001, Neurosurgery.

[9]  C. Bernards,et al.  Comparative Spinal Distribution and Clearance Kinetics of Intrathecally Administered Morphine, Fentanyl, Alfentanil, and Sufentanil , 2000, Anesthesiology.

[10]  R. Myers,et al.  Safety Assessment of Encapsulated Morphine Delivered Epidurally in a Sustained-Release Multivesicular Liposome Preparation in Dogs , 2000, Drug delivery.

[11]  L. Andrew.  Spinal cord compression by catheter granulomas in high-dose intrathecal morphine therapy: case report. , 1999 .

[12]  R. North,et al.  Neurologic Sequelae of Intraspinal Drug Delivery Systems: Results of a Survey of American Implanters of Implantable Drug Delivery Systems , 1998, Neuromodulation : journal of the International Neuromodulation Society.

[13]  G. Bejjani,et al.  Intrathecal granuloma after implantation of a morphine pump: case report and review of the literature. , 1997, Surgical neurology.

[14]  T. Hedner,et al.  Concentrations of morphine and morphine metabolites in CSF and plasma during continuous subcutaneous morphine administration in cancer pain patients , 1996, Pain.

[15]  J. Blount,et al.  Intrathecal granuloma complicating chronic spinal infusion of morphine. Report of three cases. , 1996, Journal of neurosurgery.

[16]  J. Aldrete,et al.  Paraplegia in a patient with an intrathecal catheter and a spinal cord stimulator. , 1994, Anesthesiology.

[17]  M. Rawlins,et al.  Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs , 1994, The Lancet.

[18]  D. Long,et al.  Spinal cord compression complicating subarachnoid infusion of morphine: case report and laboratory experience. , 1991, Neurosurgery.

[19]  N. Jensen,et al.  Morphine, morphine-6-glucuronide and morphine-3-glucuronide concentrations in plasma and cerebrospinal fluid during long-term high-dose intrathecal morphine administration , 1990, Pain.

[20]  T. Yaksh,et al.  Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. , 1981, Mayo Clinic proceedings.

[21]  T. Yaksh,et al.  Analgesia mediated by a direct spinal action of narcotics. , 1976, Science.

[22]  A. Langsam.  Spinal cord compression by catheter granulomas in high-dose intrathecal morphine therapy: case report. , 1999, Neurosurgery.

[23]  R. Myers,et al.  Kinetic and safety studies on intrathecally infused recombinant-methionyl human brain-derived neurotrophic factor in dogs. , 1997, Fundamental and applied toxicology : official journal of the Society of Toxicology.